14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ZLAB vs IMVT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Immunovant, Inc. (IMVT) is the stronger overall head-to-head candidate over Zai Lab Limited (ZLAB) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). ZLAB carries a Unified Composite Score of 47.4/100 (HOLD) at $23.83 (N/M Forward P/E, -63.0% operating margin), whereas IMVT carries 39.6/100 (SELL) at $33.30 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While ZLAB currently prints a higher short-term Unified Composite Score (47.4/100 HOLD vs. IMVT 39.6/100 SELL), IMVT captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -63.0% operating margin) and revenue trajectory (+0.0% vs. -6.8% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ZLAB vs IMVT. Trailing 12-month operating profitability (ZLAB -63.0% vs IMVT 0.0%) and valuation multiples (ZLAB N/M vs IMVT N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $7.3B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ZLAB vs IMVT Key Questions & Quantitative Answers
As of Nov 16, 2026, Immunovant, Inc. (IMVT) is the stronger overall head-to-head candidate over Zai Lab Limited (ZLAB) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). ZLAB carries a Unified Composite Score of 47.4/100 (HOLD) at $23.83 (N/M Forward P/E, -63.0% operating margin), whereas IMVT carries 39.6/100 (SELL) at $33.30 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While ZLAB currently prints a higher short-term Unified Composite Score (47.4/100 HOLD vs. IMVT 39.6/100 SELL), IMVT captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -63.0% operating margin) and revenue trajectory (+0.0% vs. -6.8% YoY).
IMVT leads the Growth & Scale pillar: ZLAB posts -6.8% YoY revenue growth and +0.0% YoY earnings growth on $442M TTM revenue (0.6% gross margin, -63.0% operating margin), compared with IMVT at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ZLAB generates $442M in USD-normalized revenue versus N/A for IMVT. In operating R&D and SG&A reinvestment, ZLAB deploys 63.6% of Rev ($281M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IMVT.
ZLAB screens cheaper on headline valuation multiples. ZLAB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.8x EV/Revenue (-59.3% EBITDA margin), whereas IMVT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ZLAB (-30.0% ROE) versus IMVT (-86.5% ROE) capital efficiency.
In options market volatility and institutional positioning, ZLAB carries 58.4% implied volatility (58th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 78% Vol realized risk). By comparison, IMVT carries 54.1% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.74β · 72% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.